Literature DB >> 27063445

Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.

Masako Uchii1, Naoya Kimoto2, Mariko Sakai1, Tetsuya Kitayama1, Shunji Kunori3.   

Abstract

Although previous studies have shown an important role of renal dipeptidyl peptidase-4 (DPP-4) inhibition in ameliorating kidney injury in hypertensive rats, the renal distribution of DPP-4 and mechanisms of renoprotective action of DPP-4 inhibition remain unclear. In this study, we examined the effects of the DPP-4 inhibitor saxagliptin on DPP-4 activity in renal cells (using in situ DPP-4 staining) and on renal gene expression related to inflammation and fibrosis in the renal injury in hypertensive Dahl salt-sensitive (Dahl-S) rats. Male rats fed a high-salt (8% NaCl) diet received vehicle (water) or saxagliptin (12.7mg/kg/day) for 4 weeks. Blood pressure (BP), serum glucose and 24-h urinary albumin and sodium excretions were measured, and renal histopathology was performed. High salt-diet increased BP and urinary albumin excretion, consequently resulting in glomerular sclerosis and tubulointerstitial fibrosis. Although saxagliptin did not affect BP and blood glucose levels, it significantly ameliorated urinary albumin excretion. In situ staining showed DPP-4 activity in glomerular and tubular cells. Saxagliptin significantly suppressed DPP-4 activity in renal tissue extracts and in glomerular and tubular cells. Saxagliptin also significantly attenuated the increase in inflammation and fibrosis-related gene expressions in the kidney. Our results demonstrate that saxagliptin inhibited the development of renal injury independent of its glucose-lowering effect. Glomerular and tubular DPP-4 inhibition by saxagliptin was associated with improvements in albuminuria and the suppression of inflammation and fibrosis-related genes. Thus, local glomerular and tubular DPP-4 inhibition by saxagliptin may play an important role in its renoprotective effects in Dahl-S rats.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fibrosis; Inflammation; Kidney injury; Renal dipeptidyl peptidase-4; Saxagliptin

Mesh:

Substances:

Year:  2016        PMID: 27063445     DOI: 10.1016/j.ejphar.2016.04.005

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes.

Authors:  Scott C Thomson; Volker Vallon
Journal:  Curr Diab Rep       Date:  2018-04-13       Impact factor: 4.810

2.  Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Ameliorates Angiotensin II-Induced Cardiac Diastolic Dysfunction in Male Mice.

Authors:  Scott M Brown; Cassandra E Smith; Alex I Meuth; Maloree Khan; Annayya R Aroor; Hannah M Cleeton; Gerald A Meininger; James R Sowers; Vincent G DeMarco; Bysani Chandrasekar; Ravi Nistala; Shawn B Bender
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

Review 3.  Use of Anti-Diabetic Agents in Non-Diabetic Kidney Disease: From Bench to Bedside.

Authors:  Sungjin Chung; Gheun-Ho Kim
Journal:  Life (Basel)       Date:  2021-04-25

4.  Linagliptin unmasks specific antioxidant pathways protective against albuminuria and kidney hypertrophy in a mouse model of diabetes.

Authors:  Netanya Y Spencer; Zhihong Yang; Jensyn Cone Sullivan; Thomas Klein; Robert C Stanton
Journal:  PLoS One       Date:  2018-07-06       Impact factor: 3.240

5.  Effect of Saxagliptin on Endothelial Function in Patients with Type 2 Diabetes: A Prospective Multicenter Study.

Authors:  Masato Kajikawa; Tatsuya Maruhashi; Takayuki Hidaka; Shogo Matsui; Haruki Hashimoto; Yuji Takaeko; Yukiko Nakano; Satoshi Kurisu; Yasuki Kihara; Farina Mohamad Yusoff; Shinji Kishimoto; Kazuaki Chayama; Chikara Goto; Kensuke Noma; Ayumu Nakashima; Takafumi Hiro; Atsushi Hirayama; Kazuki Shiina; Hirofumi Tomiyama; Shusuke Yagi; Rie Amano; Hirotsugu Yamada; Masataka Sata; Yukihito Higashi
Journal:  Sci Rep       Date:  2019-07-15       Impact factor: 4.379

6.  Linagliptin Regulates the Mitochondrial Respiratory Reserve to Alter Platelet Activation and Arterial Thrombosis.

Authors:  Yi Li; Rong Li; Ziqian Feng; Qin Wan; Jianbo Wu
Journal:  Front Pharmacol       Date:  2020-11-30       Impact factor: 5.810

7.  Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases.

Authors:  Ayano Kubo; Teruo Hidaka; Maiko Nakayama; Yu Sasaki; Miyuki Takagi; Hitoshi Suzuki; Yusuke Suzuki
Journal:  BMC Nephrol       Date:  2020-09-18       Impact factor: 2.388

8.  Saxagliptin Attenuates Albuminuria by Inhibiting Podocyte Epithelial- to-Mesenchymal Transition via SDF-1α in Diabetic Nephropathy.

Authors:  Yun-Peng Chang; Bei Sun; Zhe Han; Fei Han; Shao-Lan Hu; Xiao-Yu Li; Mei Xue; Yang Yang; Li Chen; Chun-Jun Li; Li-Ming Chen
Journal:  Front Pharmacol       Date:  2017-11-01       Impact factor: 5.810

Review 9.  Targeting Dermal Fibroblast Subtypes in Antifibrotic Therapy: Surface Marker as a Cellular Identity or a Functional Entity?

Authors:  Xin Huang; Yimin Khoong; Chengyao Han; Dai Su; Hao Ma; Shuchen Gu; Qingfeng Li; Tao Zan
Journal:  Front Physiol       Date:  2021-07-15       Impact factor: 4.566

10.  The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model.

Authors:  Shen-Chih Wang; Xiang-Yu Wang; Chung-Te Liu; Ruey-Hsing Chou; Zhen Bouman Chen; Po-Hsun Huang; Shing-Jong Lin
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.